Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing lumateperone, which is in Phase 3 clinical trial for the treatment of major depressive disorder, as well as schizophrenia in pediatric patients, bipolar disorder, and irritability associated with autism spectrum disorder. In addition, the company develops lenrispodun (ITI-214) in Phase 2 clinical trial for the treatment of Parkinson’s disease; ITI-1284-ODT-SL in Phase 2 trial for the treatment of generalized anxiety disorder, and psychosis and agitation in patients with Alzheimer’s disease; ITI-1020 in Phase 1 trial for cancer immunotherapy; and ITI-1549 in preclinical studies for mood and anxiety disorders.